📊 SKVI Key Takeaways
Is Skinvisible, Inc.. (SKVI) a Good Investment?
SKVI exhibits critical financial distress with negative stockholders' equity of -$10.3M, indicating technical insolvency. The company generates minimal revenue ($20K) while burning $1.1M in annual losses and faces acute liquidity crisis with 0.01x current ratio and $2.6K cash against $10.4M in liabilities. Absent dramatic operational turnaround or major capital injection, the company faces severe going-concern risk.
Why Buy Skinvisible, Inc.. Stock? SKVI Key Strengths
- 100% gross margin demonstrates pricing power on revenue generated
- Ongoing SEC compliance and regulatory reporting
- Established debt relationships indicating prior credit market access
SKVI Stock Risks: Skinvisible, Inc.. Investment Risks
- Negative stockholders' equity of -$10.3M: liabilities exceed assets by order of magnitude, technical insolvency
- Catastrophic liquidity position: 0.01x current ratio with $2.6K cash against $10.4M liabilities
- Unsustainable burn: -$42.5K free cash flow on $20K revenue, -$1.1M net loss, operating losses of $496K
Key Metrics to Watch
- Quarterly revenue trajectory and pipeline commercialization activity
- Monthly cash burn rate and remaining liquidity runway
- Capital injection, debt restructuring, or merger/acquisition announcements
Skinvisible, Inc.. (SKVI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SKVI Profit Margin, ROE & Profitability Analysis
SKVI vs Healthcare Sector: How Skinvisible, Inc.. Compares
How Skinvisible, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Skinvisible, Inc.. Stock Overvalued? SKVI Valuation Analysis 2026
Based on fundamental analysis, Skinvisible, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Skinvisible, Inc.. Balance Sheet: SKVI Debt, Cash & Liquidity
SKVI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Skinvisible, Inc..'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.52 indicates the company is currently unprofitable.
SKVI Revenue Growth, EPS Growth & YoY Performance
SKVI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.0K | -$250.2K | N/A |
| Q2 2025 | $5.0K | -$274.4K | N/A |
| Q1 2025 | $5.0K | -$281.0K | N/A |
| Q3 2024 | $5.0K | -$276.1K | $-0.06 |
| Q2 2024 | $5.0K | -$276.1K | $-0.06 |
| Q1 2024 | $5.0K | -$290.4K | $-0.06 |
| Q3 2023 | $5.0K | -$191.7K | $-0.06 |
| Q2 2023 | $5.0K | -$191.7K | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Skinvisible, Inc.. Dividends, Buybacks & Capital Allocation
SKVI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Skinvisible, Inc.. (CIK: 0001085277)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SKVI
What is the AI rating for SKVI?
Skinvisible, Inc.. (SKVI) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SKVI's key strengths?
Claude: 100% gross margin demonstrates pricing power on revenue generated. Ongoing SEC compliance and regulatory reporting.
What are the risks of investing in SKVI?
Claude: Negative stockholders' equity of -$10.3M: liabilities exceed assets by order of magnitude, technical insolvency. Catastrophic liquidity position: 0.01x current ratio with $2.6K cash against $10.4M liabilities.
What is SKVI's revenue and growth?
Skinvisible, Inc.. reported revenue of $20.0K.
Does SKVI pay dividends?
Skinvisible, Inc.. does not currently pay dividends.
Where can I find SKVI SEC filings?
Official SEC filings for Skinvisible, Inc.. (CIK: 0001085277) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SKVI's EPS?
Skinvisible, Inc.. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SKVI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Skinvisible, Inc.. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SKVI stock overvalued or undervalued?
Valuation metrics for SKVI: ROE of N/A (sector avg: 15%), net margin of -5,320.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SKVI stock in 2026?
Our dual AI analysis gives Skinvisible, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SKVI's free cash flow?
Skinvisible, Inc..'s operating cash flow is $-38.4K, with capital expenditures of $4.1K. FCF margin is -212.5%.
How does SKVI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,320.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.01 (avg: 2).